1
=
-
Vertex Pharmaceuticals Inc
As of May 18, 2026 at 24:05 UTC
Chart
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Market Statistics
Trading Metrics
How to Buy VRTX
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy VRTX
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesCRISPR Therapeutics has bullish analyst sentiment with Piper Sandler's Edward Tenthoff setting a $110 price target, implying over 100% upside. The biotech's prospects are supported by upcoming clinical trial data for CTX611 (an anticoagulant targeting a $20B market), expansion of its approved Casgevy gene therapy to children, and a deep pipeline. However, the stock remains risky due to dependence on positive clinical results and execution.
The personalized medicine market is projected to grow from USD 524 billion in 2025 to USD 1 trillion by 2034, driven by advances in genomics, AI-powered diagnostics, and targeted therapies. North America leads the market with 41% share, while Asia-Pacific emerges as a key growth engine. Major pharmaceutical and biotech companies are investing heavily in precision medicine solutions across oncology, rare diseases, and chronic conditions.
Vertex Pharmaceuticals has been a strong long-term performer but faces challenges with slowing growth in its core cystic fibrosis business and struggles diversifying into new markets. However, the company shows promise with upcoming approvals for gene-editing therapy Casgevy and kidney disease treatment povetacicept, which could drive future growth and make it attractive at current levels.
The article analyzes two underperforming healthcare stocks as potential buying opportunities: Intuitive Surgical and Vertex Pharmaceuticals. Despite recent headwinds including tariffs, increased competition, and portfolio diversification challenges, both companies have strong long-term prospects. Intuitive Surgical maintains leadership in robotic-assisted surgery with a vast addressable market, while Vertex Pharmaceuticals has a stable cystic fibrosis business and promising pipeline candidates. Both stocks are trading around $425-$460, allowing investors to purchase two shares with $1,000.
The article recommends three healthcare stocks for building long-term wealth: Johnson & Johnson, which is focusing on pharmaceuticals and medtech with strong sales growth and a 64-year dividend history; Vertex Pharmaceuticals, a leader in cystic fibrosis treatments with successful expansion into other areas; and UnitedHealth Group, which is recovering from previous challenges through better pricing, operational improvements, and AI efficiency gains.
